Welcome to our dedicated page for COGNITION THERAPEUTICS news (Ticker: CGTX), a resource for investors and traders seeking the latest updates and insights on COGNITION THERAPEUTICS stock.
Cognition Therapeutics, Inc. develops clinical-stage drug candidates for neurodegenerative disorders, with news centered on zervimesine (CT1812), an investigational oral small molecule designed to protect neuronal synapses from toxic protein oligomers. Company updates commonly address dementia with Lewy bodies, Alzheimer’s disease, mild cognitive impairment, and geographic atrophy secondary to dry AMD.
Recurring developments include Phase 2 study data from programs such as SHIMMER and START, regulatory interactions with U.S. and European agencies, scientific conference presentations, expanded access activity, and quarterly financial results. News also covers NIH-related grant funding, cash runway commentary, and clinical-development plans tied to zervimesine’s use across central nervous system and retina indications.
Cognition Therapeutics, Inc. completed enrollment in the Phase 2 SHIMMER study of CT1812 for mild-to-moderate dementia with Lewy bodies. Top-line results are expected in the second half of 2024. The study aims to develop a disease-modifying therapy for DLB by targeting Aβ and α-synuclein oligomers.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.